The burden of Clostridioides difficile on COVID‐19 hospitalizations in the USA

Clostridioides difficile infection (CDI) is the leading cause of hospital acquired‐infectious diarrhea in the USA. In this study, we assess the prevalence and impact of CDI in COVID‐19 hospitalizations in the USA.

[1]  N. Freedman,et al.  Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021. , 2022, JAMA internal medicine.

[2]  K. Takeda,et al.  Longitudinal alterations of the gut mycobiota and microbiota on COVID-19 severity , 2022, BMC Infectious Diseases.

[3]  J. Goeman,et al.  Comparison of trends in Clostridioides difficile infections in hospitalised patients during the first and second waves of the COVID-19 pandemic: A retrospective sentinel surveillance study , 2022, The Lancet Regional Health - Europe.

[4]  T. Borody,et al.  Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity , 2022, BMJ open gastroenterology.

[5]  V. Puro,et al.  The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis , 2021, Anaerobe.

[6]  Laura Martin,et al.  PD32-09 SOCIOECONOMIC PREDICTORS OF RECEIVING A VAGINAL HYSTERECTOMY COMPARED TO OPEN AND LAPAROSCOPIC/ROBOTIC APPROACHES FOR TREATMENT OF APICAL PROLAPSE: AN ANALYSIS OF OVER 38,000 WOMEN IN THE HEALTHCARE COST AND UTILIZATION PROJECT (HCUP) , 2021 .

[7]  C. Vlad,et al.  Impact of COVID-19 prevention measures on Clostridioides difficile infections in a regional acute care hospital , 2021, Experimental and therapeutic medicine.

[8]  N. Javed,et al.  COVID-19 and Fulminant Clostridium difficile Colitis Co-Infection. , 2021, European journal of case reports in internal medicine.

[9]  A. Hristea,et al.  Healthcare-associated Clostridioides difficile infection during the COVID-19 pandemic in a tertiary care hospital in Romania , 2021, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[10]  P. Patel,et al.  Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic? , 2021, Anaerobe.

[11]  Hong-Gang Li,et al.  Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery , 2021, Frontiers in Nutrition.

[12]  R. Gómez Huelgas,et al.  Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID , 2021, PloS one.

[13]  N. Novotny,et al.  Impact of Clostridium difficile infection on pediatric appendicitis , 2021, Pediatric Surgery International.

[14]  G. Ippolito,et al.  16S rRNA gene sequencing of rectal swab in patients affected by COVID-19 , 2021, PloS one.

[15]  C. Hur,et al.  Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19 , 2021, Digestive Diseases and Sciences.

[16]  M. Skally,et al.  The other ‘C’: Hospital-acquired Clostridioides difficile infection during the coronavirus disease 2019 (COVID-19) pandemic , 2021, Infection Control & Hospital Epidemiology.

[17]  K. Chow,et al.  Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 , 2021, Gut.

[18]  A. Galindo-Fraga,et al.  Substantial reduction of healthcare facility-onset Clostridioides difficile infection (HO-CDI) rates after conversion of a hospital for exclusive treatment of COVID-19 patients , 2020, American Journal of Infection Control.

[19]  S. Woolf,et al.  COVID-19 as the Leading Cause of Death in the United States. , 2020, JAMA.

[20]  Stuart Johnson,et al.  The Burden of Clostridioides Difficile Infection during the COVID-19 Pandemic: A Retrospective Case-Control Study in Italian Hospitals (CloVid) , 2020, Journal of clinical medicine.

[21]  R. Urman,et al.  Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives , 2020, Best Practice & Research Clinical Anaesthesiology.

[22]  M. Simmaco,et al.  Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection , 2020, American Journal of Infection Control.

[23]  Yichun Fu,et al.  Hospital-onset Clostridioides difficile infections during the COVID-19 pandemic , 2020, Infection Control & Hospital Epidemiology.

[24]  M. Abate,et al.  Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury , 2020, American Journal of Kidney Diseases.

[25]  M. Ponce-Alonso,et al.  Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection , 2020, Infection Control & Hospital Epidemiology.

[26]  M. Sjoding,et al.  Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice , 2020, Science Translational Medicine.

[27]  K. H. Chan,et al.  Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020 , 2020, Emerging infectious diseases.

[28]  Lanjuan Li,et al.  Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity , 2020, Engineering.

[29]  L. Diebel,et al.  Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020 , 2020, Emerging infectious diseases.

[30]  Rong Lin,et al.  Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes , 2020, The American journal of gastroenterology.

[31]  D. Gerding,et al.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. , 2020, The New England journal of medicine.

[32]  Xiaolong Qi,et al.  Real estimates of mortality following COVID-19 infection , 2020, The Lancet Infectious Diseases.

[33]  M. Kachrimanidou,et al.  Insights into the Role of Human Gut Microbiota in Clostridioides difficile Infection , 2020, Microorganisms.

[34]  W. Glasheen,et al.  Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. , 2019, American health & drug benefits.

[35]  N. Wenger,et al.  The Association of Inpatient Occupancy with Hospital-Acquired Clostridium difficile Infection , 2018, Journal of hospital medicine.

[36]  A. Delgado,et al.  Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals , 2017, BMC Infectious Diseases.

[37]  H. Nair,et al.  Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis , 2017, Journal of global health.

[38]  G. Trikudanathan,et al.  Impact of Clostridium difficile infection in patients hospitalized with acute pancreatitis- a population based cohort study. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[39]  Myung-Gyu Kim,et al.  Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection , 2015, The Korean journal of internal medicine.

[40]  C. Stone,et al.  Outcomes of Clostridium difficile Infection in Hospitalized Leukemia Patients: A Nationwide Analysis , 2015, Infection Control & Hospital Epidemiology.

[41]  H. Qu,et al.  Clostridium difficile infection in diabetes. , 2014, Diabetes research and clinical practice.

[42]  A. Ananthakrishnan,et al.  Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[43]  A. Gardner,et al.  Mortality and Clostridium difficile infection: a review , 2012, Antimicrobial Resistance and Infection Control.

[44]  J Jaime Caro,et al.  The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. , 2007, Infection control and hospital epidemiology.

[45]  W. Wierzba,et al.  Clostridioides difficile infection in coronavirus disease 2019 (COVID-19): an underestimated problem? , 2021 .

[46]  E. Goldstein,et al.  Aetiology of antimicrobial-agent-associated colitis. , 1978, Lancet.